– Training will consist of an interactive clinical education program highlighting real world application of the SynCardia Total Artificial Heart in advanced heart failure patients –TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands-On Training ...

Invitation-only program at Houston Methodist, one of the top heart transplant centers in the U.S., highlights the growing need for SynCardia Total Artificial Heart technology. Training initiative at Houston Methodist is expected to enable expanded adoption of the SynCardia Total Artificial Heart through further education. TUCSON, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first ...

- Successful heart transplant case following an implanted SynCardia total artificial heart reported at hospital with one of the largest heart transplant programs in the country -TUCSON, Ariz., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that University of California, San Francisco (UCSF) Health ...

TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th Intern ...

TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company’s fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. S ...

Core Viewpoint - Picard Medical, Inc. is actively participating in key healthcare conferences, highlighting its leadership in total artificial heart technology and its commitment to advancing medical innovation [1][4]. Group 1: Conference Participation - Picard Medical will attend the 44th Annual J.P. Morgan Healthcare Conference, including events such as LifeSci Advisors' Corporate Access Event and Lifeblood and Goodwin's CEO-Only MedTech Forum [1]. - The Lifeblood and Goodwin's MedTech CEO-Only Forum is scheduled for January 12, 2026, as an invite-only discussion forum in San Francisco, CA [3]. - The LifeSci Advisors 15th Annual Corporate Access Event will take place on January 14, 2026, featuring one-on-one meetings at The Beacon Grand, San Francisco, CA [3]. Group 2: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized for its SynCardia Total Artificial Heart (STAH), the only commercially available total artificial heart technology for patients with end-stage heart failure [4]. - The SynCardia Total Artificial Heart is the first artificial heart approved by both the FDA and Health Canada, and it is the only commercially available artificial heart in the United States and Canada [4]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [4].

Core Insights - Picard Medical, Inc. has announced the election of Patrick NJ Schnegelsberg as a member of the Board of Directors of the Arizona Bioindustry Association (AZBio), with his term extending through December 2028 [1][2] Company Overview - Picard Medical is the parent company of SynCardia Systems, which is known for developing the world's first total artificial heart approved by both the U.S. FDA and Health Canada [1][5] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart in the U.S. and Canada, with over 2,100 implants performed across 27 countries, making it the most widely used and studied artificial heart globally [5] Industry Context - Arizona is recognized as a significant hub for life sciences innovation, with AZBio playing a crucial role in fostering collaboration and growth within the industry [2][4] - The AZBio Association aims to promote the growth of Arizona bioscience companies and serves as a unified voice for the bioscience industry in the state [4]

Core Viewpoint - Picard Medical, Inc. has announced a definitive agreement for a private placement financing of up to $50 million in senior secured notes due 2028, along with warrants for common stock purchase [1][2]. Group 1: Financing Details - The company plans to issue an initial $15 million principal amount of notes at closing, with an option to fund an additional $35 million in one or more tranches, subject to certain conditions [2]. - The notes will be senior secured obligations of the company, indicating a priority claim on assets in case of liquidation [2]. Group 2: Use of Proceeds - The net proceeds from this financing will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is known for its SynCardia Total Artificial Heart, the first artificial heart approved by both the U.S. FDA and Health Canada [4]. - SynCardia's technology is the only commercially available total artificial heart for patients with end-stage heart failure, with over 2,100 implants performed across 27 countries, making it the most widely used artificial heart globally [4].

Core Viewpoint - Picard Medical, Inc. has transitioned to public markets and is committed to advancing its Total Artificial Heart technology for patients with end-stage heart failure [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona and is the leader in total artificial heart technology for end-stage heart failure patients [3]. - SynCardia has developed the SynCardia Total Artificial Heart (STAH), the first artificial heart approved by both the FDA and Health Canada, and remains the only commercially available artificial heart in the U.S. and Canada [3]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and studied artificial heart globally [3]. Transition to Public Markets - The company will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking its transition to being a publicly traded entity [1]. - The CEO of Picard Medical expressed pride in this transition, emphasizing that it strengthens the company's ability to advance its artificial heart platform, including the fully implantable Emperor system [2]. Future Outlook - The transition to a public company is seen as an important phase for Picard Medical, as it aims to build on decades of clinical leadership and create long-term value through the advancement of next-generation technology [2].

Core Insights - Picard Medical, Inc. is the parent company of SynCardia Systems LLC, which produces the world's first total artificial heart approved by both the U.S. FDA and Health Canada [1][3] - CEO Patrick NJ Schnegelsberg will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt, Germany, on December 6, 2025 [1][2] Company Overview - Picard Medical, Inc. is based in Tucson, Arizona, and is a leader in total artificial heart technology for patients with end-stage heart failure [3] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart in the U.S. and Canada, having been implanted over 2,100 times across 27 countries, making it the most widely used and studied artificial heart globally [3]